Haploidentical Transplantation in Severe Aplastic Anemia
A Research on Haploidentical Transplantation in Severe Aplastic Anemia Using Reduced-intensity Fludarabine-based Conditioning
This is a prospective case-control study on SAA patients treated with HSCT, order to further discuss and assess the safety, feasibility and effectiveness of HFD-HSCT which performed with reduced-intensity fludarabine-based conditioning regimen.Our findings would indicate that SAA patients who lack MSD benefited most if HFD-HSCT was performed with reduced-intensity fludarabine-based conditioning regimen, and our improved outcomes with HFD-HSCT may lead to a salvaged therapy and an expanded direct role for SAA in the future.
Severe Aplastic Anemia
Study Arms / Comparison Groups
Description: This group received treatment of matched sibling donor - hematopoietic stem cell transplantation (MSD-HSCT).
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
July 10, 2017
December 1, 2020
Primary Completion Date
July 1, 2020
Inclusion Criteria: (i) Diagnosis of SAA, very SAA or SAA and paroxysmal nocturnal hemoglobinuria (PNH) according to the International Aplastic Anemia Study Group; (ii) SAA patients no response to previous IST; (iii) adequate performance status [Eastern Cooperative Oncology Group (ECOG) score 0-2]. Exclusion Criteria: (i) Congenital forms of aplastic anemia; (ii)Patients with any severe pulmonary, cardiac, liver, or renal diseases or active infection.
N/A - N/A
Accepts Healthy Volunteers
Xiaoxiong WU, PhD, ,
Xiaoxiong WU, PhD, Study Director, The First Affiliated Hospital of General Hospital of PLA